Xin Miao1, Gilbert Koch1, Robert M Straubinger1, William J Jusko2. 1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA. 2. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, 14214, USA. wjjusko@buffalo.edu.
Abstract
PURPOSE: This study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines and proposes a pharmacodynamic (PD) model to quantify their pharmacological interactions. METHODS: Effects of gemcitabine and trabectedin upon the pancreatic cancer cell lines MiaPaCa-2 and BxPC-3 were investigated using cell proliferation assays. Cells were exposed to a range of concentrations of the two drugs, alone and in combination. Viable cell numbers were obtained daily over 5 days. A model incorporating nonlinear cytotoxicity, transit compartments, and an interaction parameter ψ was used to quantify the effects of the individual drugs and combinations. RESULTS: Simultaneous fitting of temporal cell growth profiles for all drug concentrations provided reasonable cytotoxicity parameter estimates (the cell killing rate constant K max and the sensitivity constant KC50) for each drug. The interaction parameter ψ was estimated as 0.806 for MiaPaCa-2 and 0.843 for BxPC-3 cells, suggesting that the two drugs exert modestly synergistic effects. CONCLUSIONS: The proposed PD model enables quantification of the temporal profiles of drug combinations over a range of concentrations with drug-specific parameters. Based upon these in vitro studies, trabectedin may have augmented benefit in combination with gemcitabine. The PD model may have general relevance for the study of other cytotoxic drug combinations.
PURPOSE: This study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines and proposes a pharmacodynamic (PD) model to quantify their pharmacological interactions. METHODS: Effects of gemcitabine and trabectedin upon the pancreatic cancer cell lines MiaPaCa-2 and BxPC-3 were investigated using cell proliferation assays. Cells were exposed to a range of concentrations of the two drugs, alone and in combination. Viable cell numbers were obtained daily over 5 days. A model incorporating nonlinear cytotoxicity, transit compartments, and an interaction parameter ψ was used to quantify the effects of the individual drugs and combinations. RESULTS: Simultaneous fitting of temporal cell growth profiles for all drug concentrations provided reasonable cytotoxicity parameter estimates (the cell killing rate constant K max and the sensitivity constant KC50) for each drug. The interaction parameter ψ was estimated as 0.806 for MiaPaCa-2 and 0.843 for BxPC-3 cells, suggesting that the two drugs exert modestly synergistic effects. CONCLUSIONS: The proposed PD model enables quantification of the temporal profiles of drug combinations over a range of concentrations with drug-specific parameters. Based upon these in vitro studies, trabectedin may have augmented benefit in combination with gemcitabine. The PD model may have general relevance for the study of other cytotoxic drug combinations.
Authors: K L Rinehart; T G Holt; N L Fregeau; P A Keifer; G R Wilson; T J Perun; R Sakai; A G Thompson; J G Stroh; L S Shield Journal: J Nat Prod Date: 1990 Jul-Aug Impact factor: 4.050
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Mark S Duxbury; Hiromichi Ito; Michael J Zinner; Stanley W Ashley; Edward E Whang Journal: Clin Cancer Res Date: 2004-04-01 Impact factor: 12.531
Authors: Monica Simeoni; Paolo Magni; Cristiano Cammia; Giuseppe De Nicolao; Valter Croci; Enrico Pesenti; Massimiliano Germani; Italo Poggesi; Maurizio Rocchetti Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Thinzar M Lwin; Ho Kyoung Hwang; Jonathan C Delong; Bryan M Clary; Michael Bouvet; Michiaki Unno; Robert M Hoffman Journal: Oncotarget Date: 2017-07-18
Authors: Tim Cardilin; Joachim Almquist; Mats Jirstrand; Astrid Zimmermann; Floriane Lignet; Samer El Bawab; Johan Gabrielsson Journal: Cancer Chemother Pharmacol Date: 2019-04-11 Impact factor: 3.333
Authors: Tim Cardilin; Joachim Almquist; Mats Jirstrand; Astrid Zimmermann; Floriane Lignet; Samer El Bawab; Johan Gabrielsson Journal: J Pharmacokinet Pharmacodyn Date: 2021-10-08 Impact factor: 2.745
Authors: Tim Cardilin; Joachim Almquist; Mats Jirstrand; Astrid Zimmermann; Samer El Bawab; Johan Gabrielsson Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-12-14